Montefiore Einstein Center for Cancer Care
Welcome,         Profile    Billing    Logout  
 26 Trials 
170 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ferrari, Anna C
NCT01251861: Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Checkmark ESMO 2016
Oct 2016 - Oct 2016: ESMO 2016
Active, not recruiting
2
108
Europe, US
Akt Inhibitor MK2206, MK 2206, MK-2206, MK-2206 FREE BASE, MK2206, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Clinical Observation, observation, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7
07/18
03/25
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Active, not recruiting
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
06/24
06/24
Goel, Sanjay
NCT04137107: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Recruiting
2/3
348
US, RoW
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
02/25
12/25
NCT04393454: Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Terminated
2
6
US
Sirolimus 2Mg Tab
Albert Einstein College of Medicine
Metastatic dMMR Solid Cancer, Solid Tumor, Cancer, Metastatic Solid Tumor
05/23
05/23
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Recruiting
2
215
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
12/24
03/25
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
NCT04565275: A Study of ICP-192 in Patients With Advanced Solid Tumors

Recruiting
1/2
45
US, RoW
Drug ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
11/23
04/24
XTX202-01, NCT05052268: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc.
Advanced Solid Tumor
02/26
02/26
DF1001-001, NCT04143711: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics
Solid Tumor, Adult
10/26
12/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT06028074: Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
111
US
GIM122, GIM-122
Georgiamune Inc
Advanced Solid Malignancies
09/26
12/26
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT04412616: ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

Recruiting
1
60
US, RoW
ZZ06
Changchun Intellicrown Pharmaceutical Co. LTD, Covance
Advanced EGFR Positive Solid Tumor
12/23
04/24
NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Recruiting
1
226
US, RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Advanced Solid Tumors
12/23
12/23
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT05831995: Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Recruiting
1
112
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
10/25
10/25
Feldman, Sheldon
NCT04815083: Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Recruiting
3
370
US
Aminolevulinic Acid Hydrochloride, PD G 506 A, Eagle V1.2 Imaging System, Placebo
SBI ALApharma Canada, Inc.
Breast Neoplasm Female, Breast Cancer
05/25
06/26
TBCRC 042, NCT02928978: Ruxolitinib for Premalignant Breast Disease

Recruiting
2
100
US
Ruxolitinib, Jakafi, INCB018424, Placebo (for Ruxolitinib)
Julie Nangia, Incyte Corporation, Translational Breast Cancer Research Consortium
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
12/24
01/25
NCT01901562: Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge

Terminated
N/A
9
US
Ductoscopic papillectomy
Montefiore Medical Center, Columbia University
Breast Discharge Infected, Intraductal Papilloma of Breast
01/17
01/17
SHADES, NCT04549571: Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

Recruiting
N/A
700
US
Decision Aid iCanDecide - ESE website, Decision Aid iCanDecide - S website, Therapeutic Conventional Surgery, Interview, Training, Media Intervention, Best Practice, Survey Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/25
01/27
Bruno, Debora
Be6A Lung-01, NCT06012435: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT04181060: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Recruiting
3
300
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD-9291, AZD9291, Mereletinib
National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/26
12/26
EA5163, NCT03793179: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active, not recruiting
3
600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/28
12/28
NCT05198830: Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Recruiting
2
42
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methoxyamine, TRC102 Base, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
12/25
12/25
NCT03831932: Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruiting
1/2
28
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Elastography, MRE, Osimertinib, AZD-9291, AZD9291, Mereletinib, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Telaglenastat Hydrochloride, CB-839 HCl, Glutaminase Inhibitor CB-839 Hydrochloride, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
06/25
06/25
DF1001-001, NCT04143711: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics
Solid Tumor, Adult
10/26
12/26
NCT02955290: CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Checkmark Results for adv NSCLC in combination with CIMAvax-EGF
Jan 2019 - Jan 2019: Results for adv NSCLC in combination with CIMAvax-EGF
Recruiting
1/2
242
US
Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine, Center of Molecular Immunology Epidermal Growth Factor Vaccine, Cimavax, CIMAvax EGF, CIMAvax Epidermal Growth Factor Vaccine, CIMAvax-EGF, Recombinant Human EGF-P64K/Montanide Vaccine
Roswell Park Cancer Institute
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
12/27
12/27
NCT03818776: Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Terminated
1
7
US
Durvalumab, MEDI4736, Proton beam therapy RT
Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
01/22
01/22
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
NCT05701085: Patient Navigator PRE-ACT Educational Intervention to Promote Decision Making Among Minorities

Recruiting
N/A
240
US
Educational Intervention
Case Comprehensive Cancer Center
Educational Intervention, Minorities
12/24
12/26
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
19
US
Oxybutynin, Gelnique
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Recruiting
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
12/24
04/25
NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Recruiting
4
336
Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
03/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Recruiting
4
200
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
09/24
10/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT04994535: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
Allergan
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Active, not recruiting
3
1321
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin single dose, Dalbavancin two dose, Comparator
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
12/23
12/23
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Active, not recruiting
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1080
Europe, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
05/37
05/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Calendar Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Calendar Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Active, not recruiting
3
429
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
03/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Active, not recruiting
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
08/24
08/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting
3
880
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Dupilumab
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
07/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
09/27
09/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
US
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/25
03/26
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
US
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Active, not recruiting
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Calendar Jan 2024 - Dec 2024: Data readout from TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Calendar Jan 2024 - Dec 2024: Submission for r/r myelofibrosis in combination with Jakafi (based on TRANSFORM-2 trial)
Active, not recruiting
3
295
Europe, Canada, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
11/24
01/25
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide 72 μg (FC Participants), Placebo (FC Participants), Linaclotide 145 μg (IBS-C Participants), Linaclotide 290 μg (IBS-C Participants)
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Active, not recruiting
3
132
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
12/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Recruiting
3
152
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
11/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Recruiting
3
116
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
08/25
11/25
NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
12/24
06/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Recruiting
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
12/24
04/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Active, not recruiting
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
10/24
10/24
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Active, not recruiting
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Recruiting
3
1500
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
05/25
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
06/25
03/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Recruiting
3
156
Europe, Canada
ELAPR002f Injectable Gel, Saline Control
AbbVie
Atrophic Acne Scars
08/25
08/25
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Recruiting
3
280
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting
3
480
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
09/25
08/26
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
3
1328
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa
11/25
08/27
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
08/26
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Recruiting
3
276
Europe, Canada, Japan, US, RoW
Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab
AbbVie
Crohn's Disease
03/26
02/28
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Recruiting
3
1059
US
Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant
AbbVie
Migraine
05/26
05/26
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

Recruiting
3
520
Europe, Canada, RoW
Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate
AbbVie
Migraine
06/26
06/26
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting
3
16
US
Paricalcitol
AbbVie
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
06/26
10/26
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Recruiting
3
40
Europe, US
Adalimumab, Risankizumab, ABBV-066, Skyrizi
AbbVie
Juvenile Psoriatic Arthritis
09/26
10/28
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
3
1000
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, Placebo
AbbVie
Systemic Lupus Erythematosus
10/26
10/27
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Active, not recruiting
3
424
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC)
AbbVie
Acute Myeloid Leukemia (AML), Cancer
11/26
11/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/27
12/29
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
3
90
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, ABT-494, Tocilizumab
AbbVie
Juvenile Idiopathic Arthritis
02/27
06/29
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting
3
450
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant
AbbVie
Episodic Migraine
03/28
05/28
NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Recruiting
3
110
Europe, Japan, US, RoW
Upadacitinib, RINVOQ
AbbVie
Ulcerative Colitis
08/28
10/33
NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Recruiting
3
110
Europe, US, RoW
Risankizumab, ABBV-066, SKYRIZI
AbbVie
Crohn's Disease
04/29
04/29
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Enrolling by invitation
3
250
Europe, Canada, Japan, US, RoW
Atogepant, QULIPTA, AGN-241689
AbbVie
Episodic Migraine
11/29
11/29
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Epcoritamab, GEN3013, Rituximab, Lenalidomide
Genmab, AbbVie
Follicular Lymphoma (FL)
11/29
06/30
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Recruiting
2/3
2800
US
Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4
AbbVie
Hypothyroidism
06/28
06/28
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Hourglass Sep 2021 - Dec 2021 : Data from trial in combination with Navocaftor and ABBV-119 for cystic fibrosis
Terminated
2
48
Europe, US, RoW
ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119
AbbVie
Cystic Fibrosis (CF)
06/23
06/23
AIM-CD, NCT05068284: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Calendar Jan 2024 - Dec 2024: Data from AIM-CD trial for Crohn’s disease
Terminated
2
176
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo
AbbVie
Crohn's Disease
07/23
07/23
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Recruiting
2
95
Europe, Canada, US
Eluxadoline, Viberzi, Placebo
AbbVie
Irritable Bowel Syndrome
12/26
12/26
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

Recruiting
2
30
Europe
ELAPR002f Injectable Gel
AbbVie
Skin Quality Deficit
01/25
01/25
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Completed
2
13
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Thermal Burn
03/24
03/24
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Recruiting
2
100
RoW
YL201 for Injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
02/27
02/29
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Recruiting
2
200
Japan, US
Lutikizumab Matching Placebo, Adalimumab Matching Placebo, Lutikizumab, ABT-981, Adalimumab, Humira
AbbVie
Ulcerative Colitis
04/27
04/27
NCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Recruiting
2
30
Europe, US, RoW
Linaclotide, Linzess, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation
09/25
09/25
NCT05141006: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Active, not recruiting
2
83
Canada, US
BOTOX, OnabotulinumtoxinA, Botulinum Toxin Type A, Placebo for BOTOX
Allergan
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
07/24
02/25
NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
01/25
04/25
NCT05771428: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Active, not recruiting
2
240
Europe, Japan, US, RoW
ABBV-552, Placebo for ABBV-552
AbbVie
Alzheimer's Disease (AD)
08/24
09/24
 

Download Options